Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044824 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
A Phase 3 study of Asthma, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 7
- Study locations
NCT00044824 is a Phase 3 study of Asthma that has completed, run by Sanofi. The registered enrollment target is 1,000 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (36% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT00044824, a Phase 3 study of Asthma, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
Conditions Studied
Interventions
- DRUG Fexofenadine
Study Locations (7)
Other
- Sanofi-Aventis Admnistrative Office - Costa Rica
- Sanofi-Aventis Administrative Office - Guatemala City
- sanofi-aventis Hungaria - Budapest
- Sanofi-Aventis Administrative Office - México
- sanofi-aventis Poland - Warsaw
- Sanofi-Aventis Aministrative Office - Moscow
New Jersey
- Aventis Pharmaceuticals Inc. - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044824
The ClinicalTrials.gov registry entry for NCT00044824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (36% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Fexofenadine is the first listed.
NCT00044824 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00044824 about?
NCT00044824 is a clinical study titled "Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma". The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
What is the current status of trial NCT00044824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2002-02. Estimated completion is 2003-10.
What conditions does trial NCT00044824 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00044824?
The interventions under investigation include: Fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00044824?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044824 being conducted?
This trial has 7 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.